Medindia

X

New JardianceŽ (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes

Sunday, June 12, 2016 Heart Disease News J E 4
Advertisement
- In a separate analysis, JARDIANCE also reduced risk for CV events consistently in groups divided by LDL cholesterol level

Eli Lilly and Company logo.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
New NHANES Analysis Shows No Improvement in Last D...
S
Semaglutide Demonstrated Superior Improvements in ...